PROTEA-PFONCT07172464
Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study
At risk: Primary completion moved at least 11 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Aug 2026 to Aug 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 9 words
- Study completion pushed from Feb 2031 to Feb 2032
- Study sites: 5 to 4
- Secondary endpoints: details revised at 1 of 2 entries
- Notable Enrollment increased: 15 → 30 participants
- Site details revised at 2 of 5 sites
- Minor Study sites: 4 to 5
- Start date changed from estimate of Sep 2025 to Oct 9, 2025
- Minor Study sites: 3 to 4v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Primary Safety Endpoint - Rate of Major Adverse Cardiovascular Events (MACE)
Timeframe: 30 days
Primary Performance Endpoint - Effective PFO Closure
Timeframe: 6 months
Secondary (2)
Secondary Safety Endpoints - Rate of device-related or procedure-related Serious Adverse Events (SAEs)
Secondary Performance Endpoint - Correct device position
Arms and interventions
Recross P3 Occluder (P3O) SystemExperimental
The Recross P3 Occluder (P3O) is being developed for the purpose of transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients with PFO-associated stroke.
Devices: Recross P3 Occluder (P3O) System
Sites
4 sites in 1 country